KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview.
Jakupec
M A
MA
Institute of Inorganic Chemistry - Bioinorganic, Environmental and Radiochemistry, University of Vienna, Austria.
Arion
V B
VB
Kapitza
S
S
Reisner
E
E
Eichinger
A
A
Pongratz
M
M
Marian
B
B
Graf von Keyserlingk
N
N
Keppler
B K
BK
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D017209:Apoptosis; D045744:Cell Line, Tumor; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007191:Indazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D009942:Organometallic Compounds; D010084:Oxidation-Reduction; D017975:Ruthenium Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D014168:Transferrin / Q000378:metabolism
D000970:Antineoplastic Agents; D007191:Indazoles; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; D014168:Transferrin; C499292:indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III))